Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million
15/12/2025 13:13
Dec 15 (Reuters) - Adaptive Biotechnologies ADPT.O said on Monday it has signed two non-exclusive deals with Pfizer PFE.N to support research in rheumatoid arthritis and other immune-related diseases.
Adaptive said it will earn up to $890 million, including upfront fees and milestone payments tied to research progress, product development and sales.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Krishna Chandra Eluri)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on Adaptive Biotechnologies
See all newsBrief: Adaptive Biotechnologies Corp - Issues $345 Million In 0% Convertible Senior Notes Due 2031 - SEC Filing
U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron
U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron
U.S. STOCKS ON THE MOVE-Intel, La-Z-Boy, CME
U.S. STOCKS ON THE MOVE-Intel, La-Z-Boy, AST SpaceMobile